bcbsil glp 1 coverage bcbs change bcbs illinois glp 1 coverage The GLP-1 Access Gap: Mapping Who Can Actually Afford America's 2026 Pharmacy Benefits | Blue

The tirzepatide dosing guide covers this standard escalation in full detail

Weight gain and weight-loss resistance may involve insulin response, energy expenditure, fat storage, inflammation, sleep patterns, stress hormones, genetics, and lifestyle habits

When asked about whether they expected the Trump administrations policies to lower the cost of prescription drugs for people like them, most (62%) say it is either not too likely or not at all likely, while nearly four in 10 (38%) say it is very or somewhat likely. Those expectations are largely driven by partisanship

Typical criteria include: Documented diagnosis of type 2 diabetes with inadequate glycemic control on metformin or other first-line agents BMI 27 kg/m with weight-related comorbidity or BMI 30 kg/m (for weight management indications) Trial and failure of alternative therapies Absence of contraindications Coverage for weight management indications under commercial plans has expanded but remains inconsistent, with many employers specifically excluding obesity medications from pharmacy benefits

The FDA issued a February 2026 statement that it "intends to take action against non-FDA-approved GLP-1 drugs." As brand-name supply stabilizes, the legal justification for mass-compounding (which requires a drug shortage) weakens

But these ingredients aren't FDA-approved, and there's no evidence that they are safe or effective